Literature DB >> 10721016

Establishing health state valuations for disease specific states: an example from heart disease.

J Kirsch1, A McGuire.   

Abstract

This study considers the feasibility of defining a QALY from disease-specific data using the New York Heart Association (NYHA) classification of heart failure. The study derives health state values for the four different NYHA classifications of disease progression using the time trade-off (TTO) instrument associated with the five dimensional (EQ-5D) health state valuation method. Consistent mappings between the disease classification and the chosen QALY instrument are found. With this being the case, the assumption of constant proportionality, which is necessary to define the QALY as an acceptable measure of health related preferences, is considered. It is found that constant proportionality does not hold across the more severe health states, thus questioning the use of QALYs as representing cardinal preference structures. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10721016     DOI: 10.1002/(sici)1099-1050(200003)9:2<149::aid-hec501>3.0.co;2-n

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  16 in total

1.  Cost-utility analysis of 21-gene assay for node-positive early breast cancer.

Authors:  L Masucci; S Torres; A Eisen; M Trudeau; I Tyono; H Saunders; K W Chan; W Isaranuwatchai
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

2.  Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.

Authors:  F Lennie Wong; Smita Bhatia; Wendy Landier; Liton Francisco; Wendy Leisenring; Melissa M Hudson; Gregory T Armstrong; Ann Mertens; Marilyn Stovall; Leslie L Robison; Gary H Lyman; Steven E Lipshultz; Saro H Armenian
Journal:  Ann Intern Med       Date:  2014-05-20       Impact factor: 25.391

3.  What should we know about the person behind a TTO?

Authors:  Floortje van Nooten; Jan Busschbach; Michel van Agthoven; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2018-12

4.  On the (not so) constant proportional trade-off in TTO.

Authors:  Arthur E Attema; Werner B F Brouwer
Journal:  Qual Life Res       Date:  2010-02-12       Impact factor: 4.147

5.  Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.

Authors:  M Ekman; N Zethraeus; B Jönsson
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.

Authors:  Nikos Maniadakis; Mattias Ekman; Vasilios Fragoulakis; Vasiliki Papagiannopoulou; John Yfantopoulos
Journal:  Eur J Health Econ       Date:  2010-04-22

7.  Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea.

Authors:  Eun-A Lim; Hyun-Soon Sohn; Haeyoung Lee; Sang-Eun Choi
Journal:  Cost Eff Resour Alloc       Date:  2014-09-10

Review 8.  A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure.

Authors:  F Tomini; F Prinzen; A D I van Asselt
Journal:  Eur J Health Econ       Date:  2016-01-04

9.  Validation study of the prototype of a disease-specific index measure for health-related quality of life in dementia.

Authors:  Carla J M Schölzel-Dorenbos; Alexander M M Arons; Joost J G Wammes; Marcel G M Olde Rikkert; Paul F M Krabbe
Journal:  Health Qual Life Outcomes       Date:  2012-09-25       Impact factor: 3.186

10.  Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus.

Authors:  Klemens Wallner; A M James Shapiro; Peter A Senior; Christopher McCabe
Journal:  BMC Endocr Disord       Date:  2016-04-09       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.